Page 8 - Patrick Barth News Today

Share: Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional OCREVUS dosing regimen Shorter infusion time will further improve the twice-yearly treatment experience for OCREVUS, the only B-cell therapy for relapsing and primary progressive MS with a twice-yearly dosing schedule Basel, 14 December 2020 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter t...

(2) Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional OCREVUS dosing regimen Shorter infusion time will further improve the twice-yearly treatment experience for OCREVUS, the only B-cell therapy for relapsing and primary progressive MS with a twice-yearly dosing schedule Basel, 14 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-...

The Elecsys® SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infectionRoche will be able to ramp up to a double-digit million number of tests per

F. Hoffmann-La Roche Ltd: Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 25.8 DFS, HR (95% CI) (0.19-0.60) About bladder cancer and muscle-invasive urothelial cancer In 2018, there were over half a million new cases of bladder cancer diagnosed globally, with approximately 200,000 deaths from the disease. 4 Urothelial cancer is the most common type of bladder cancer, accounting for about 90-95% of all...

F. Hoffmann-La Roche Ltd Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq mono...

tonight on "worldfocus" -- a wave of explosions pummel baghdad killing and wounding hundreds. whats happening to the security america has spent and sacrificed to bring about? how to measure success in americas other war in afghanistan. the obama administration prepares its first progress report. well take you airborne to look at an extraordinary effort by the u.s. military to save lives in the middle of a war, welcome aboard an air ambulance. and germany wants a million electri...

> tonight on the "worldfocus" -- a wave of explosions pummel baghdad killg and wouing hundreds. whats happening to the security america has spent and sacrifice to bringabout? how to measure success in americas other warn afanistan. ares its first progress report. well take you airborne to look a an extraordinary effort by the u.s. military to save lives in t middle of the war, welcome aboard anir amlance. d germanyants a million ectric vehiclesn the road by 2020. well plug you...

tonight on the "worldfocus" -- a wave of explosions pummel baghdad killing and wounding hundreds. whats happening to the security america has spent and sacrificed to bring about? how to measure success in americas other war in afghanistan. ares its first progress report. well take you airborne to look at an extraordinary effort by the u.s. military to save lives in the middle of the war, welcome aboard an air ambulance. and germany wants a million electric vehicles on the road ...